Bliss GVS Pharma (506197) Q2 26/27 earnings summary

Executive summary

• Q2 FY27 revenue reached 26,112.98 lakh standalone and 31,336.70 lakh consolidated; reported net profit was 7,356.54 lakh and 5,334.20 lakh, respectively.

• H1 FY27 consolidated revenue was 59,894.26 lakh and net profit 10,471.40 lakh; standalone net profit included a 4,108.61 lakh impairment reversal.

Financial highlights

• Standalone Q2 revenue was 26,112.98 lakh vs 19,022.53 lakh YoY; net profit was 7,356.54 lakh vs 3,861.77 lakh.

• Consolidated Q2 revenue was 31,336.70 lakh vs 24,439.85 lakh YoY; net profit was 5,334.20 lakh vs 2,858.86 lakh.

• Standalone H1 revenue was 48,271.49 lakh vs 35,358.96 lakh; net profit was 11,218.31 lakh vs 4,584.48 lakh.

• Consolidated H1 revenue was 59,894.26 lakh vs 45,186.77 lakh; net profit was 10,471.40 lakh vs 7,294.99 lakh.

• Q2 basic EPS was 6.93 standalone and 4.92 consolidated; H1 basic EPS was 10.58 and 9.65, respectively.

Segment performance

• Operations comprise one operating segment: Pharmaceutical and Healthcare.